Heart-Saving hope for neuroendocrine cancer patients in new drug trial
NCT ID NCT04810091
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 33 times
Summary
This study tests whether adding telotristat ethyl to standard therapy can help prevent or control heart damage caused by carcinoid syndrome in people with advanced neuroendocrine tumors. About 79 adults whose cancer has spread and who are already on stable somatostatin analog therapy will receive either telotristat ethyl plus standard care or standard care alone. The main goal is to see if the drug lowers a heart stress marker (NT-proBNP) after 6 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED NEUROENDOCRINE NEOPLASM are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.